ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

Firm Wins Patent For Method, Apparatus For Cryoablation.

December 15, 2000

Funding Opportunities: NCI Offers Funds To Develop, Validate Mouse Models

November 20, 1998

New Atlas Showing nonwhite Mortality Rates Available

January 7, 1977

DCE Advisors OK Concepts for Registry, Grants In Breast Cancer

June 25, 1993

Major Changes In NCI Drug screening Tumor Panels Approved

June 18, 1982

Large Studies Show Promising Results For Targeted Therapies Alimta, Tarceva

June 26, 2009